Get the Stockscreener App
4.69
0.21%
0.01
After Hours:
5.07
0.38
+8.10%
Rocket Pharmaceuticals Inc stock is traded at $4.69, with a volume of 6.91M.
It is up +0.21% in the last 24 hours and up +3.53% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$4.68
Open:
$4.65
24h Volume:
6.91M
Relative Volume:
2.59
Market Cap:
$509.19M
Revenue:
-
Net Income/Loss:
$-223.12M
P/E Ratio:
-2.3339
EPS:
-2.0095
Net Cash Flow:
$-190.49M
1W Performance:
+6.83%
1M Performance:
+3.53%
6M Performance:
+43.87%
1Y Performance:
-39.01%
1-Day Range:
$4.625
$5.14
1-Week Range:
$4.10
$5.14
52-Week Range:
$2.19
$8.26
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
4.69 | 508.10M | 0 | -223.12M | -190.49M | -2.0095 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 9.3%Should You Buy? - MarketBeat
Rocket Pharmaceuticals advances year round advocacy with EveryLife Foundation partnership - Traders Union
Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? - MSN
RCKT (Rocket Pharmaceuticals) asks shareholders to elect directors, ratify auditor, approve option exchange - Stock Titan
Gene therapy for inborn immune errors takes center stage in Rocket Pharmaceuticals expert forum - Traders Union
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Jobs Data: Is Rocket Pharmaceuticals Inc Equity Warrant a cyclical or defensive stockPortfolio Update Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Aug Closing: Is Rocket Pharmaceuticals Inc Equity Warrant a turnaround story2026 Growth vs Value & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Aug Decliners: Will Rocket Pharmaceuticals Inc benefit from sector rotation2026 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Forecast Cut: Should you avoid Rocket Pharmaceuticals Inc stock right nowQuarterly Trade Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Aug Wrap: What are analysts price targets for Rocket Pharmaceuticals Inc2026 Short Interest & Consistent Profit Trading Strategies - baoquankhu1.vn
RCKT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Rocket Pharma Advances BAG3 Heart Disease Study, Bolstering Long-Term Gene Therapy Story - TipRanks
Recap Report: Is now the right time to enter Rocket Pharmaceuticals Inc Equity WarrantExit Point & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Drivers: Can Rocket Pharmaceuticals Inc expand into new markets2026 Bull vs Bear & Expert Curated Trade Setups - baoquankhu1.vn
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.4%Here's What Happened - MarketBeat
Rocket Pharmaceuticals to present LAD I advances at primary immune deficiency workshop - Traders Union
Morgan Stanley names Rocket Pharmaceuticals (RCKT) as key beneficiary of 2026 biotech sector recovery - MSN
RCKT's Q4 loss narrower than estimated, pipeline in focus - MSN
Suvretta Capital Management LLC Cuts Position in Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Rocket Pharmaceuticals, Inc. $RCKT Holdings Trimmed by Prosight Management LP - MarketBeat
Chart Watch: Is Rocket Pharmaceuticals Inc forming a bullish divergence2026 Levels & Fast Gain Swing Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Stock Drops Pre-Market After FDA Pauses Gene Therapy Trial Over Patient Death: Retail Turns Bullish - MSN
Insider Buy: Is Rocket Pharmaceuticals Inc part of any ETF2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Enters New Sales Agreement with Cantor Fitzgerald, Terminates Prior Equity Offering Arrangement - Minichart
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 4.8%Should You Sell? - MarketBeat
Rocket Pharmaceuticals Launches New $100M At-The-Market Program - TipRanks
[EFFECT] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Rocket Pharmaceuticals enters $100 million at-the-market offering agreement - Investing.com
Rocket Pharmaceuticals enters $100 million at-the-market offering agreement By Investing.com - Investing.com India
Rocket Pharmaceuticals (RCKT) Launches $100 Million Stock Offeri - GuruFocus
Rocket Pharmaceuticals Launches $100 Million ATM Offering With Cantor Fitzgerald - TradingView
According to the latest filing with the U.S. Securities and Exchange Commission, biotechnology company Rocket Pharmaceuticals, Inc. has officially signed an equity sales agreement with renowned financial institution Cantor Fitzgerald & Co. - Bitget
Rocket Pharmaceuticals (RCKT) launches $100M at-the-market stock offering with Cantor - Stock Titan
Form 424B5 ROCKET PHARMACEUTICALS, - StreetInsider
Rocket Pharmaceuticals (RCKT) launches up to $100M ATM offering with Cantor - Stock Titan
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 5.4%What's Next? - MarketBeat
UniQure leads genetic medicine biotech rally after news of Prasad’s exit - BioPharma Dive
Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at Wall Street Zen - MarketBeat
Short Covering: Is Rocket Pharmaceuticals Inc Equity Warrant attractive for institutional investorsDollar Strength & Low Drawdown Investment Ideas - baoquankhu1.vn
Weekly Recap: Is Rocket Pharmaceuticals Inc showing insider buyingQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
RCKT SEC FilingsRocket Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
rocket pharmaceuticals continuing to perform - Moomoo
RCKT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Canaccord Genuity Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Rocket gene therapy among at least 7 PDUFA dates at FDA in March - BioCentury
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances - Yahoo! Finance Canada
Rocket Pharmaceuticals (NASDAQ: RCKT) files $400M shelf to raise capital - Stock Titan
Goldman Sachs Maintains 'Sell' Rating on RCKT, Raises Price Targ - GuruFocus
The Goldman Sachs Group Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):